Loading
What changed between revision 3 and revision 5, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 3
Import
Re-import of content/ai-drug-discovery.md — the file changed after the initial import. Not an edit.
20.4 kB
Revision 3
Revision 5
lines 8–18 → 8–187 unchanged lines not shown
categories: ["foundations", "longevity"]categories: ["foundations", "longevity"]tags: ["machine learning", "drug development", "generative chemistry", "target discovery", "clinical trials", "pharmacology"]tags: ["machine learning", "drug development", "generative chemistry", "target discovery", "clinical trials", "pharmacology"]summary: "The use of machine learning to select drug targets, generate candidate molecules and predict failure, so far demonstrably faster at making compounds than at making medicines."summary: "The use of machine learning to select drug targets, generate candidate molecules and predict failure, so far demonstrably faster at making compounds than at making medicines."updated: "2026-08-22"updated: "2026-10-28"humanEvidence: "AI-derived small molecules have reached phase 1 and 2 trials, with a first phase 3 begun in 2026; sponsors of an mRNA therapy built on algorithm-selected neoantigens report a phase 3 in melanoma met its endpoints, and no drug from either route is approved."humanEvidence: "AI-derived small molecules have reached phase 1 and 2 trials, with a first phase 3 begun in 2026; sponsors of an mRNA therapy built on algorithm-selected neoantigens report a phase 3 in melanoma met its endpoints, and no drug from either route is approved."access: "Platforms are proprietary to pharmaceutical companies or licensed to them, and some models and datasets are public; no molecule designed this way is available outside a trial, though AI-suggested uses of approved drugs are."access: "Platforms are proprietary to pharmaceutical companies or licensed to them, and some models and datasets are public; no molecule designed this way is available outside a trial, though AI-suggested uses of approved drugs are."reversibility: "context"reversibility: "context"issues: ["Needs a citable source for the absence of any approved AI-discovered drug.", "The phase 1 to approval rate is uncited; Cook 2014 supports the efficacy-failure point only.", "The INTerpath-001 paragraph rests on a topline company announcement; detailed data are not yet published."]issues: ["Needs a citable source for the absence of any approved AI-discovered drug.", "The phase 1 to approval rate is uncited; Cook 2014 supports the efficacy-failure point only.", "The INTerpath-001 paragraph rests on a topline company announcement; detailed data are not yet published.", "The Anthropic case results are company-reported only; no independent verification exists."]------ ```infobox```infoboxlines 69–78 → 69–9350 unchanged lines not shown
**Structure and synthesis.** Protein structure prediction, covered under [[ai-protein-design]],**Structure and synthesis.** Protein structure prediction, covered under [[ai-protein-design]],opened pocket-based design to proteins with no experimental structure, though benchmark studies ofopened pocket-based design to proteins with no experimental structure, though benchmark studies ofdocking have found predicted structures to perform worse than experimental ones. Retrosynthesisdocking have found predicted structures to perform worse than experimental ones. The companybuilt most directly on AlphaFold is [[isomorphic-labs|Isomorphic Labs]], the Alphabet spin-out fromDeepMind that co-developed AlphaFold 3; despite partnerships with three large drug companies, noneof its molecules had entered a human trial as of October 2026. Retrosynthesismodels propose routes, sometimes coupled to automated synthesis platforms so that design, make andmodels propose routes, sometimes coupled to automated synthesis platforms so that design, make andtest run as a closed loop.test run as a closed loop. **Operational and regulatory work.** Several tasks around the chemistry carry no molecule design atall: compiling manufacturing records, drafting regulatory filings, designing and assessing trials,coordinating work across contract laboratories. These are where developers of general-purposelanguage and agent models have entered the field, by a different route from Alphabet's, which spunits drug-design work out into a separate company. Anthropic reported in October 2026 on researchpartnerships with six drug developers — BigHat Biosciences, Bristol Myers Squibb, Divergence Labs,Enveda, Generate Biomedicines and The Column Group — and on programmes of its own, having acquiredMithril Medicine, a one-person company working on two rare forms of muscular dystrophy whose founderhad used the company's Claude models to coordinate experiments across eleven externallaboratories.[^anthropic2026] Anthropic's stated reasoning is that the bottlenecks are distributedthrough the whole development process rather than concentrated in molecule design. ## Development history## Development history ```timeline```timelinelines 124–129 → 139–15845 unchanged lines not shown
generating a new chemical entity, so whether the result counts as an AI-derived drug succeeding ingenerating a new chemical entity, so whether the result counts as an AI-derived drug succeeding inphase 3 depends entirely on where the label's boundary is drawn.phase 3 depends entirely on where the label's boundary is drawn. The newest claims for the approach are not near patients at all. Anthropic's October 2026 reportmixes molecule-design results — roughly 35,000 antibody designs generated for Divergence Labs inabout a month, about 1,010 antibody variants made and tested with BigHat Biosciences over about tenweeks, a shortened genetic component of a CAR T-cell therapy that Generate Biomedicines aims toextend to [[cancer|solid tumours]] — with operational ones, among them a manufacturing-documentreview at Enveda that the company says cut human review time by 89%, and an assessment ofclinical-trial plans at Bristol Myers Squibb. Every figure is reported by the companies themselves,and Anthropic describes the work as early and mostly preclinical: nothing from it has entered ahuman trial, and the earliest first-in-human date the company offers, late 2028, is conditional onits candidates continuing to hold up. Its furthest-advanced internal programme, a bispecificantibody for a form of congenital muscular dystrophy, rests on a pilot study in mice whoseaccompanying technical report states that it was not peer reviewed and that the experiments wereneither randomized nor blinded. > [!caution] What "AI-discovered" means> [!caution] What "AI-discovered" means> No regulator recognizes the category, and companies apply the label to everything from a molecule> No regulator recognizes the category, and companies apply the label to everything from a molecule> drawn by a generative model to a conventional campaign in which a classifier filtered one plate.> drawn by a generative model to a conventional campaign in which a classifier filtered one plate.lines 240–245 → 269–275110 unchanged lines not shown
[^richardson2020]: `paper` Richardson, P. et al. "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease." *The Lancet*, 2020. {Baricitinib was already approved for rheumatoid arthritis, so the system reranked known pharmacology rather than proposing a new molecule.}[^richardson2020]: `paper` Richardson, P. et al. "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease." *The Lancet*, 2020. {Baricitinib was already approved for rheumatoid arthritis, so the system reranked known pharmacology rather than proposing a new molecule.}[^zhavoronkov2019]: `paper` Zhavoronkov, A. et al. "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 2019. {DDR1 was a well-precedented target and the compounds resembled known inhibitors; chemists disputed how much of the speed the model explained.}[^zhavoronkov2019]: `paper` Zhavoronkov, A. et al. "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 2019. {DDR1 was a well-precedented target and the compounds resembled known inhibitors; chemists disputed how much of the speed the model explained.}[^stokes2020]: `paper` Stokes, J.M. et al. "A Deep Learning Approach to Antibiotic Discovery." *Cell*, 2020. {Halicin's activity was confirmed in mouse infection models; it has not entered human trials.}[^stokes2020]: `paper` Stokes, J.M. et al. "A Deep Learning Approach to Antibiotic Discovery." *Cell*, 2020. {Halicin's activity was confirmed in mouse infection models; it has not entered human trials.}[^anthropic2026]: `statement` Anthropic. "Early progress on accelerating drug development with Claude." Company blog post, October 27, 2026, with the accompanying technical report by Tranbarger, C. and Mithril Medicine on a bispecific bridging antibody for LAMA2-related congenital muscular dystrophy, October 26, 2026. {Every result is the companies' own; the technical report is marked not peer reviewed and its mouse pilot was neither randomized nor blinded.}[^xu2025]: `paper` Xu, Z. et al. "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial." *Nature Medicine*, 2025. {Seventy-one patients across three dose arms and placebo, treated for twelve weeks; a trial that size and length cannot establish clinical benefit in fibrosis.}[^xu2025]: `paper` Xu, Z. et al. "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial." *Nature Medicine*, 2025. {Seventy-one patients across three dose arms and placebo, treated for twelve weeks; a trial that size and length cannot establish clinical benefit in fibrosis.}[^insilico2026]: `statement` Insilico Medicine. "Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis." Press release, July 2026. {Announces trial initiation only, not results; a 320-patient, 52-week randomized placebo-controlled study at Chinese centres.}[^insilico2026]: `statement` Insilico Medicine. "Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis." Press release, July 2026. {Announces trial initiation only, not results; a 320-patient, 52-week randomized placebo-controlled study at Chinese centres.}[^merck2026]: `statement` Merck and Moderna. "Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Patients With Completely Resected Stage IIB–IV Melanoma." Joint press release, August 19, 2026. {A topline interim-analysis announcement; hazard ratios and detailed results were not disclosed with it.}[^merck2026]: `statement` Merck and Moderna. "Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Patients With Completely Resected Stage IIB–IV Melanoma." Joint press release, August 19, 2026. {A topline interim-analysis announcement; hazard ratios and detailed results were not disclosed with it.}removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
250 lines are the same in both revisions, and 220 of them are not shown. Neither revision here is necessarily the current article — read AI drug discovery for the text this wiki stands behind today.